VENTAC PARTNERS IS A DEDICATED LIFE SCIENCE CONSULTING FIRM WITH OFFICES IN EUROPE, USA AND ASIA.

Ventac Partners has a strong track record in founding new innovative companies, strategic and operational market and product analysis, intellectual property development, fund raising, licensing, M&A and strategy consulting.

All partners are experienced executives from pharma, biotech and medtech companies, and preclinical, clinical and regulatory, legal and intellectual property experts with extensive backgrounds in successfully starting, growing and expanding international life science companies.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Latest News
July, 2015 | Avexxin Completes Phase I/IIa Study In Psoriasis and Achieves Proof-of-Concept with AVX001 in a topical formulation, see Portfolio News.

June, 2015 | Idogen shares and warrants start trading on Swedish stock exchange AktieTorget, see Portfolio News.

March, 2015 | APIM Therapeutics completes a new financing round; funds will be used to finalize preclinical development of ATX-101, see Portfolio News.

November, 2014 | Ventac Partners and Lacerta Bio merge to expand global coverage in life sciences and strengthen USA positioning, see VP News.

 

Newsblitz

Clinical Network Services (CNS) Pty Ltd
Clinical Network Services (CNS), an integrated service consultancy focusing on preclinical and early clinical project implementation and Ventac Partners sign cooperative partnership to provide joint services to global clients (download services flyer here).

For more information, see our joint press release.